FDA warned OraLabs, an OTC drugmaker in Parker, Colorado, that it skipped microbial release testing and dismissed contamination findings.
What happened
FDA inspected OraLabs' drug manufacturing facility in Parker, Colorado, from September 22 to 26, 2025. Investigators found the company released multiple batches of over-the-counter drug products without microbiological release testing, and that its quality unit approved and shipped those lots. FDA also found the company's investigations into microbial test failures were incomplete, including one where high total aerobic counts identified as Bacillus cereus were set aside as invalid without sound scientific reason.
What FDA found
The company released batches of OTC drugs without testing them for objectionable microorganisms, and did so only when a customer asked.
21 CFR 211.165(b)The company wrote a memo concluding no microbial testing was needed, even though its own records showed microbial growth in its products.
21 CFR 211.165(b)The company threw out a high total aerobic count result that identified Bacillus cereus, without adequate scientific justification.
21 CFR 211.192Investigations into microbial test failures often ended with no clear root cause, no environmental sampling, and weak corrective actions, yet the lots were still released.
21 CFR 211.192
What FDA wants
Within 15 working days, respond in writing with what has been corrected and how recurrence will be prevented. FDA also asks for independent assessments of the lab and manufacturing operations, a risk assessment of already-distributed product, completed investigations of contaminated batches, and testing of retained samples of all unexpired U.S. batches.
Who should pay attention
- brands that use OraLabs as a contract manufacturer of OTC drugs
- retailers and distributors selling store-brand OTC products made at this site
- quality teams at other OTC makers that rely on customer-request-only microbial testing
This is a summary. Read the original letter on fda.gov.